Guanfacine alone and in combination therapy in the treatment of moderate and severe hypertension.
This study of guanfacine in 27 patients suffering from moderate-to-severe hypertension showed a satisfactory blood pressure control in 26 patients. Twenty-one of the 27 patients completed a one-year clinical trial with good blood pressure response. The new drugs, acting through the stimulation of the central alpha-adrenoceptors, are useful in patients suffering from moderate-to-severe hypertension. They are a good alternative to adrenergic neuron-blocking drugs, methyldopa, or beta-blockers, and useful in patients with refractory hypertension where conventional therapy has failed.
D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001581:Benzothiadiazines; D002986:Clinical Trials as Topic; D004232:Diuretics; D004359:Drug Therapy, Combination; D016316:Guanfacine; D006146:Guanidines / Q000008:administration & dosage*; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage; D006973:Hypertension / Q000188:drug therapy; D010648:Phenylacetates / Q000008:administration & dosage*; D010869:Pindolol / Q000008:administration & dosage; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage
D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D004232:Diuretics; D006146:Guanidines; D010648:Phenylacetates; D049993:Sodium Chloride Symporter Inhibitors; D006830:Hydralazine; D016316:Guanfacine; D010869:Pindolol